Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up

SABCS 2025

9 - 12 Dec 2025

Published: 18 Dec 2025

Views: 27

Rating:

Save

Dr Matteo Lambertini - University of Genova, Genova, Italy

Dr Matteo Lambertini presents 10-year follow-up results from the Phase 3 ALTTO trial, assessing the efficacy of different adjuvant endocrine therapies (aromatase inhibitors vs. SERMs) in patients with HR+/HER2+ early breast cancer treated with modern chemotherapy and anti-HER2 regimens.

The analysis showed that aromatase inhibitors significantly improved disease-free survival and time to distant recurrence, with benefits observed in both premenopausal and postmenopausal patients.

Related Videos

AI and pathology reveal higher late recurrence risk in invasive lobular breast...

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting...

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for...

Dr Scott Tagawa - Weill Cornell Medicine, New York, USA

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC ( Dr Scott Tagawa - Weill Cornell Medicine, New York, USA )

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients...

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )

MCED blood test demonstrates high specificity, strong predictive value, and...

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )

Enhancing breast cancer care through AI and collaboration

Dr Gabrielle Speijer, Dr Fernando Suarez and Dr Tolga Ozmen

Enhancing breast cancer care through AI and collaboration ( Dr Gabrielle Speijer, Dr Fernando Suarez and Dr Tolga Ozmen )

Disparities in mammogram screening amongst LGBTQ+ populations

Dr Manas Pustake - Texas Tech University Health Science Center, El Paso, USA

Disparities in mammogram screening amongst LGBTQ+ populations ( Dr Manas Pustake - Texas Tech University Health Science Center, El Paso, USA )

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables...

Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing ( Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA )

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy...

Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise ( Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA )

More from ecancer